KURA logo

KURA
Kura Oncology Inc

3,687
Mkt Cap
$841.58M
Volume
237,737.00
52W High
$12.49
52W Low
$5.45
PE Ratio
-2.83
KURA Fundamentals
Price
$9.75
Prev Close
$9.48
Open
$9.61
50D MA
$8.88
Beta
1.09
Avg. Volume
1.37M
EPS (Annual)
-$3.18
P/B
7.80
Rev/Employee
$259,546.15
$264.17
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available
Poll

Earnings Recap

• Reported GAAP EPS of -$0.83 down -25.76% YoY • Reported revenue of $18.27M up 29.47% YoY • Kura Oncology expects its $580.8M in cash, plus $180M in anticipated collaboration payments, to fund the ziftomenib AML program through topline KOMET-017 Phase 3 results anticipated in 2028.

Bullish

Kura Oncology's KOMZIFTI generated $5.8M in net product revenue with strong early launch momentum and over 93% payer coverage, while ziftomenib pipeline advancements promise multiple 2026 data readouts.

Bearish

Kura Oncology experienced an increased net loss of $73.3M in Q1 2026, alongside rising R&D and SG&A expenses, while KOMZIFTI carries significant safety risks including fatal differentiation syndrome and QTc prolongation.

Advertisement|Remove ads.

Advertisement|Remove ads.